News

Discover how auricular acupuncture could enhance facial aesthetics, offering non-invasive rejuvenation with rapid results and minimal downtime for wrinkle reduction.

Topical roflumilast 0.3% cream shows promise in reducing lesions and symptoms of mild hidradenitis suppurativa (HS), offering a well-tolerated treatment option.

Explore the complexities of managing hidradenitis suppurativa (HS) through real-world case studies moderated by Afsaneh Alavi, MD.

Experts discuss real-world applications of JAK inhibitors for alopecia areata, emphasizing patient selection, psychosocial impacts, and personalized treatment strategies.

The National Psoriasis Foundation (NPF) redefines psoriasis severity, emphasizing disease impact over extent, enhancing treatment access, and aligning clinical practice with patient needs.

This review of the latest dermatologic studies includes insights on the "fear of overfilling," sexual adverse events from oral finasteride, post-laser, fibronectin-based skin care regimens, and more.

The RWEAL study uncovers real-world management of chronic hand eczema (CHE), highlighting treatment gaps and the need for standardized assessment in clinical practice.

Connect Biopharma reveals innovative data on rademikibart's mechanism of action, highlighting its potential impact on atopic dermatitis and future clinical priorities.

Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.

Alpha Tau Medical advances Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC), offering a novel, localized treatment option with minimal toxicity.

Zasocitinib emerges as a highly selective and potent allosteric tyrosine kinase 2 (TYK2) inhibitor, showing promise for treating immune-mediated inflammatory diseases.

Dupilumab demonstrates significant efficacy and safety in treating severe atopic dermatitis in children aged 6 months to 5 years, improving quality of life.

New research confirms how skin tension line-oriented grafting enhances cosmetic outcomes in basal cell carcinoma surgery, improving aesthetics without compromising quality of life.

Oruka Therapeutics reveals promising interim results for ORKA-002 and launches the EVERLAST-B trial for ORKA-001, targeting chronic skin diseases.

Adelle Walker explores the future of aesthetics as personalized, holistic approaches and regenerative treatments, particularly in younger patients, reshape trends in 2026.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on phase 3 data of envudeucitinib for psoriasis, a combination treatment of ixekizumab and tirzepatide for PsA, a BLA pathway for sonelokimab in HS, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Discover how vitamin D receptor signaling influences hair follicle health and alopecia, revealing new therapeutic possibilities for hair loss management.

Discover how trifarotene could enhance acne treatment in Malaysia, addressing both facial and truncal acne while improving hyperpigmentation and scarring.

Navigator Medicines advances NAV-240 and NAV-242, targeting dual inflammation pathways for hidradenitis suppurativa in upcoming clinical trials.

A new study evaluates the quality and reliability of melasma posts on TikTok and Bilibili, highlighting gaps in treatment information and educational value.

Research reveals that structural changes in neoantigens enhance tumor rejection, offering new insights for personalized cancer immunotherapies.

Results from the TOGETHER-PsA trial reveal that combining ixekizumab and tirzepatide significantly improves outcomes for patients with psoriatic arthritis (PsA) and obesity.

MoonLake Immunotherapeutics shares promising updates on sonelokimab's efficacy for hidradenitis suppurativa.

CSU significantly impacts family quality of life, revealing the need for comprehensive care and support for both patients and their caregivers.

Jasper Therapeutics reveals promising briquilimab data, showcasing rapid disease control and safety in chronic spontaneous urticaria and chronic inducible urticaria.

Johnson & Johnson reveals JNJ-95475939's early termination due to insufficient efficacy in treating moderate to severe atopic dermatitis.

Verrica Pharmaceuticals initiates phase 3 trials for VP-102, aiming to provide an effective treatment for common warts, addressing significant unmet needs.